Anne Sisk

Diverse alterations associated with resistance to KRAS(G12C) inhibition

M. Berger, J. Reis-Filho, B. Weigelt, 2021, Nature.

Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations

H. Vargas, M. Voss, G. Iyer, 2021, Clinical Cancer Research.

Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment

A. Drilon, J. Harding, K. Jhaveri, 2022, Cancer medicine.